Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio (Nasdaq: VOR) to participate in upcoming investor conferences to discuss developments in cell and genome engineering.
04/01/2024 - 08:00 AM
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
23rd Annual Needham Virtual Healthcare Conference Fireside Chat: Tuesday, April 9, 2024 at 3:45 pm ET Location: Virtual
Chardan's 8th Annual Genetic Medicines + Cell Therapy Manufacturing Summit Fireside Chat: Monday, April 29, 2024 at 9:30 am ET Location: Virtual
About Vor Bio Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com .
Contact:
Media & Investors Sarah Spencer +1 857-242-6076sspencer@vorbio.com
When is Vor Bio participating in the 23rd Annual Needham Virtual Healthcare Conference?
Vor Bio is participating in the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:45 pm ET.
Where will the Fireside Chat for the Chardan's 8th Annual Genetic Medicines + Cell Therapy Manufacturing Summit take place?
The Fireside Chat for the Chardan's 8th Annual Genetic Medicines + Cell Therapy Manufacturing Summit will take place on Monday, April 29, 2024, at 9:30 am ET.
Vor Biopharma Inc
NASDAQ:VOR
VOR Rankings
#4827 Ranked by Stock Gains
VOR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About VOR
vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar